Verdure’s Longvida gets Brazilian approval via Kilyos Nutrition partnership

By Stephen Daniells

- Last updated on GMT

© microgen / Getty Images
© microgen / Getty Images

Related tags Curcumin Brazil ANVISA

US-based Verdure Sciences has received approval from Brazil’s ANVISA for its Longvida curcumin extract, which will be available in the South America country through an exclusive distribution partner in this territory, Kilyos Nutrition.

The Verdure-Kilyos partnership is positioned to support an expanding market targeting joint health, cognitive health, mood, sports nutrition, vascular health, and more.

Longvida (Solid Lipid Curcumin Particle - SLCP) is a patented and proprietary turmeric extract standardized to curcumin and total curcuminoids.

“We are pleased with the approval of LongVida for food supplementation. Curcumin is an ingredient of proven effectiveness in promoting health and wellness for individuals,” ​said José João Name, MD, PhD, director of Kilyos Nutrition.

“We would like to thank our partner Verdure Sciences for the opportunity of including LongVida in our portfolio and for providing us with the full support to obtain the approval of curcumin from ANVISA, for the first time in Brazil, in the food supplementation category. We most certainly will obtain incredibly good results from this partnership!”

Ajay Patel, Founder & CEO with Verdure Sciences, expressed his company’s excitement about the ANVISA announcement and the partnership with Kilyos, stating: “We are honored to offer Longvida to the Brazilian market via Kilyos and their strong customer base which includes both nutritional and pharmaceutical companies

“It is a testament to LongVida’s global acceptance and footprint which is a result of two decades of continuous investment in its safety, efficacy, quality, traceability and sustainability. In addition LongVida offers multifaceted health benefits as a result of clinical studies in healthy human subjects conducted in global demographics evaluating a multitude of biological markers.”

Related news